(Q54361471)

28 May 2018

title

Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. (English)

1 reference

28 May 2018

0 references

1 reference

Pauline Wimberger

1

1 reference

28 May 2018

Issam Chebouti

2

1 reference

28 May 2018

Sabine Kasimir-Bauer

3

1 reference

28 May 2018

Robert Lachmann

4

1 reference

28 May 2018

Eberhard Kuhlisch

5

1 reference

28 May 2018

Rainer Kimmig

6

1 reference

28 May 2018

Ergün Süleyman

7

1 reference

28 May 2018

Jan Dominik Kuhlmann

8

1 reference

28 May 2018

language of work or name

English

0 references

publication date

5 April 2014

1 reference

28 May 2018

published in

Gynecologic Oncology

1 reference

28 May 2018

volume

133

1 reference

28 May 2018

issue

3

1 reference

28 May 2018

page(s)

467-472

1 reference

28 May 2018

Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Management of recurrent ovarian carcinoma: current status and future directions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

VEGF and the quest for tumour angiogenesis factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

VEGF-targeted therapy: mechanisms of anti-tumour activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

A phase 3 trial of bevacizumab in ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Incorporation of bevacizumab in the primary treatment of ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Zone-specific remodeling of tumor blood vessels affects tumor growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor receptors VEGFR-2 and VEGFR-3 are localized primarily to the vasculature in human primary solid cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Tumor vessel stabilization and remodeling by anti-angiogenic therapy with bevacizumab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Functional significance of VEGFR-2 on ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

The role of the tumor microenvironment in regulating angiogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Biomarkers of response and resistance to antiangiogenic therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Occult tumor cells in bone marrow of patients with locoregionally restricted ovarian cancer predict early distant metastatic relapse.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone marrow of patients with ovarian cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

The VEGF receptor Flt-1 spatially modulates Flk-1 signaling and blood vessel branching.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2014.03.574

10.1016/J.YGYNO.2014.03.574

7 January 2021

Identifiers

DOI

1 reference

28 May 2018

PubMed ID

24713547

1 reference

28 May 2018